帕纳替尼治疗慢性髓性白血病的不良反应特征与结局
该回顾性研究分析了78例连续接受帕纳替尼治疗的CML患者,发现血小板减少最常见(39.7%),23.1%发生心血管不良事件(CAE),心律失常(9%)和高血压(7.7%)最常见。疗效上,主要分子学缓解率58.7%和5年OS 76%均高于PACE试验。
要点
- 帕纳替尼治疗CML中血小板减少常见(39.7%),呈剂量依赖性。
- CAE发生率为23.1%,其中心律失常9%、高血压7.7%、心肌梗死3.8%。
核心结论
- 帕纳替尼治疗CML高效,但需关注心血管不良事件,剂量调整和心脏肿瘤科转诊可能有助于最大化获益。
主要发现
- 最常见的非CAE为血小板减少(39.7%),呈剂量依赖性。
- 主要分子学缓解率58.7%,5年OS 76%,中位随访32.5个月。
关键数值与推荐
- 2014年前多数患者起始剂量为帕纳替尼45 mg每日一次。
临床怎么用
- 帕纳替尼治疗CML需监测心血管不良事件,考虑心脏肿瘤科转诊和剂量调整以降低CAE风险。
局限性
- 回顾性研究,样本量有限(78例),单中心数据。
- 2014年后CAE减少为多种因素(起始剂量降低、更频繁减量、转诊增加)共同作用,难以明确单一因素贡献。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ponatinib is associated with cardiovascular adverse events (CAEs), and its frequency in the real world is limited. In this retrospective study, we examined the survival outcomes and associated toxicities in 78 consecutive ponatinib-treated patients with chronic myeloid leukemia (CML) at the Moffitt Cancer Center from January 2011 through December 2017. The most common non-CAE was thrombocytopenia (39.7%), occurring in a dose-dependent fashion. Eighteen patients (23.1%) experienced some form of CAE, with the most common being arrhythmia (9%) and hypertension (7.7%), whereas 3 patients experienced myocardial infarction (3.8%). Before 2014, most patients were started on ponatinib 45 mg daily. There was an inverse correlation between cardio-oncology referral and the number of CAEs (P = .0440); however, a lower ponatinib starting dose, more frequent dose reduction, and increased cardio-oncology referral all were likely to have contributed to the observed decrease in CAEs after 2014. The response rate and 5-year overall survival (OS) were higher than those observed in the Ponatinib Ph+ ALL and CML Evaluation (PACE) trial (major molecular response, 58.7% vs 40% and OS, 76% vs 73%; median follow-up of 32.5 months). Ponatinib-treated patients with chronic phase-CML did not show a significant improvement with allogeneic stem cell transplantation, whereas those with accelerated phase/blast phase-CML had a much better outcome (median OS of 32.9 months vs 9.2 months; P = .01). These results demonstrate that ponatinib is highly effective. Dose adjustments and increased awareness of the cardiotoxicities associated with ponatinib may help maximize its benefits.
引用
- Chan O, Talati C, Isenalumhe L, et al. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv. 2020. PMID: 32045474. doi:10.1182/bloodadvances.2019000268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。